Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The correlation between intracranial atherosclerosis and white matter hyperintensities in cerebral small vessel disease: a high-resolution magnetic resonance imaging study.
Front Neurol
January 2025
Department of Neurology, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
Objective: Recent studies have indicated a close relationship between intracranial arterial stenosis and white matter hyperintensities (WMHs), but few have reported on the correlation between the characteristics of intracranial arterial wall plaques and WMHs. The aim of this study was to comprehensively assess the correlation between intracranial atherosclerosis plaques and WMHs using 3.0T high-resolution magnetic resonance imaging (HR-MRI).
View Article and Find Full Text PDFDesign and early progress of the Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial.
Int J Stroke
January 2025
Medical University of South Carolina, Charleston, SC, USA.
Background: The usual antithrombotic treatment for symptomatic intracranial atherosclerotic stenosis (ICAS) consists of dual treatment with clopidogrel and aspirin for 90 days followed by aspirin alone but the risk of recurrent stroke remains high up to 12 months. The Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial was designed to determine whether other combinations of dual antithrombotic therapy are superior to clopidogrel and aspirin.
Methods: CAPTIVA is an ongoing, prospective, double-blinded, three-arm clinical trial at over 100 sites in the United States and Canada that will randomize 1683 high-risk subjects with a symptomatic infarct attributed to 70-99% stenosis of a major intracranial artery to 12 months of treatment with (1) ticagrelor (180 mg loading dose, then 90 mg twice daily), (2) low-dose rivaroxaban (2.
Reactive Oxygen Species, a Potential Therapeutic Target for Vascular Dementia.
Biomolecules
December 2024
Clinical Neuroscience Research Center, Department of Neurosurgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Vascular dementia (VaD) is a progressive neurodegenerative condition prevalent among elderly adults marked by cognitive decline resulting from injured and/or improperly functioning cerebrovasculature with resultant disruptions in cerebral blood flow. Currently, VaD has no specific therapeutics and the exact pathobiology is still being investigated. VaD has been shown to develop when reactive oxygen species (ROS) form from damaged targets at different levels of organization-mitochondria, endothelial cells, or cerebrovasculature.
View Article and Find Full Text PDFCracking the Code of Calcification: How Presence and Burden among Intracranial Arteries Influence Stroke Incidence and Recurrence.
AJNR Am J Neuroradiol
January 2025
University of Padova (M.C.); University of Bologna (M.O.A.); Department of Radiology (R.C, R.S., L.S.), Azienda Ospedaliero Universitaria (A.O.U.) di Cagliari, Cagliari, Sardegna, Italy; Department of Neurology and Stroke Program (S.C.), University of Maryland School of Medicine, Baltimore, Maryland, United States; CVPath Institute (R.V.), Gaithersburg, Maryland, United States; Department of Radiology (G.DR.), Azienda San Camillo Forlanini, Rome, Lazio, Italy; Department of Epidemiology (D.B.), Erasmus Medical Center, Rotterdam, South Holland, Netherlands; Department of Radiology and Nuclear Medicine (D.B.), Erasmus Medical Center, Rotterdam, South Holland, Netherlands; Mayo Clinic (L.S.), Rochester, Minnesota, United States.
Background: Intracranial atherosclerosis accounts for about 8% of all strokes in Western societies but the influence of arterial calcification on plaque instability is a topic on ongoing debate.
Purpose: Explore the association between the presence and burden of calcium in atherosclerotic plaques among intracranial arteries with the risk of clinical or silent stroke events through a systematic review and meta-analysis.
Data Sources: Adhering to PRISMA guidelines, studies from PubMed and Embase were analyzed up to May 2024.
Alterations of amino acids in older adults with Alzheimer's Disease and Vascular Dementia.
Amino Acids
January 2025
Institute of Brain Science, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, P. R. China.
Metabolomics provide a promising tool for understanding dementia pathogenesis and identifying novel biomarkers. This study aimed to identify amino acid biomarkers for Alzheimer's Disease (AD) and Vascular Dementia (VD). By amino acid metabolomics, the concentrations of amino acids were determined in the serum of AD and VD patients as well as age-matched healthy controls.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!